Cargando…
Heated tobacco product regulation under US law and the FCTC
Tobacco companies are marketing new ‘heated tobacco products’ (HTPs) composed of battery-powered holders, chargers and tobacco plugs or sticks. The non-tobacco HTP components have escaped effective regulation under many countries’ tobacco control laws because they are packaged and sold separately fr...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204223/ https://www.ncbi.nlm.nih.gov/pubmed/30291201 http://dx.doi.org/10.1136/tobaccocontrol-2018-054560 |
_version_ | 1783366009433882624 |
---|---|
author | Lempert, Lauren Kass Glantz, Stanton A |
author_facet | Lempert, Lauren Kass Glantz, Stanton A |
author_sort | Lempert, Lauren Kass |
collection | PubMed |
description | Tobacco companies are marketing new ‘heated tobacco products’ (HTPs) composed of battery-powered holders, chargers and tobacco plugs or sticks. The non-tobacco HTP components have escaped effective regulation under many countries’ tobacco control laws because they are packaged and sold separately from the tobacco-containing components. In the USA, HTPs cannot be marketed unless the Food and Drug Administration determines that allowing their sale would be ‘appropriate for the protection of the public health’. Philip Morris International (PMI) is seeking permission to market its IQOS HTP in the USA with ‘modified risk tobacco product’ (MRTP) claims that it reduces exposure to harmful substances and is less harmful than other tobacco products. However, PMI has not submitted adequate scientific evidence required by US law to demonstrate that the product is significantly less harmful to users than other tobacco products, that its labelling would not mislead consumers, or that its marketing—with or without MRTP claims—would benefit the health of the population as a whole. Parties to the WHO Framework Convention on Tobacco Control (FCTC) must take measures to reduce tobacco use and nicotine addiction, and prevent false or misleading tobacco product labelling, advertising and promotions; the introduction of new HTPs must be assessed according to these goals. All components of HTPs should be regulated at least as stringently as existing tobacco products, including restrictions on labelling, advertising, promotion and sponsorship, sales to minors, price and taxation policies and smokefree measures. There is nothing in US law or the FCTC that prevents authorities from prohibiting HTPs. |
format | Online Article Text |
id | pubmed-6204223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62042232018-11-01 Heated tobacco product regulation under US law and the FCTC Lempert, Lauren Kass Glantz, Stanton A Tob Control Special Communication Tobacco companies are marketing new ‘heated tobacco products’ (HTPs) composed of battery-powered holders, chargers and tobacco plugs or sticks. The non-tobacco HTP components have escaped effective regulation under many countries’ tobacco control laws because they are packaged and sold separately from the tobacco-containing components. In the USA, HTPs cannot be marketed unless the Food and Drug Administration determines that allowing their sale would be ‘appropriate for the protection of the public health’. Philip Morris International (PMI) is seeking permission to market its IQOS HTP in the USA with ‘modified risk tobacco product’ (MRTP) claims that it reduces exposure to harmful substances and is less harmful than other tobacco products. However, PMI has not submitted adequate scientific evidence required by US law to demonstrate that the product is significantly less harmful to users than other tobacco products, that its labelling would not mislead consumers, or that its marketing—with or without MRTP claims—would benefit the health of the population as a whole. Parties to the WHO Framework Convention on Tobacco Control (FCTC) must take measures to reduce tobacco use and nicotine addiction, and prevent false or misleading tobacco product labelling, advertising and promotions; the introduction of new HTPs must be assessed according to these goals. All components of HTPs should be regulated at least as stringently as existing tobacco products, including restrictions on labelling, advertising, promotion and sponsorship, sales to minors, price and taxation policies and smokefree measures. There is nothing in US law or the FCTC that prevents authorities from prohibiting HTPs. BMJ Publishing Group 2018-11 2018-10-05 /pmc/articles/PMC6204223/ /pubmed/30291201 http://dx.doi.org/10.1136/tobaccocontrol-2018-054560 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Special Communication Lempert, Lauren Kass Glantz, Stanton A Heated tobacco product regulation under US law and the FCTC |
title | Heated tobacco product regulation under US law and the FCTC |
title_full | Heated tobacco product regulation under US law and the FCTC |
title_fullStr | Heated tobacco product regulation under US law and the FCTC |
title_full_unstemmed | Heated tobacco product regulation under US law and the FCTC |
title_short | Heated tobacco product regulation under US law and the FCTC |
title_sort | heated tobacco product regulation under us law and the fctc |
topic | Special Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204223/ https://www.ncbi.nlm.nih.gov/pubmed/30291201 http://dx.doi.org/10.1136/tobaccocontrol-2018-054560 |
work_keys_str_mv | AT lempertlaurenkass heatedtobaccoproductregulationunderuslawandthefctc AT glantzstantona heatedtobaccoproductregulationunderuslawandthefctc |